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Despite recent progress in understanding lamellipodia extension,
the molecular mechanisms regulating filopodia formation remain
largely unknown. Myo10 is a MyTH4-FERM myosin that localizes to
the tips of filopodia and is hypothesized to function in filopodia
formation. To determine whether endogenous Myo10 is required
for filopodia formation, we have used scanning EM to assay the
numerous filopodia normally present on the dorsal surfaces of
HeLa cells. We show here that siRNA-mediated knockdown of
Myo10 in HeLa cells leads to a dramatic loss of dorsal filopodia.
Overexpressing the coiled coil region from Myo10 as a dominant-
negative also leads to a loss of dorsal filopodia, thus providing
independent evidence that Myo10 functions in filopodia forma-
tion. We also show that expressing Myo10 in COS-7 cells, a cell line
that normally lacks dorsal filopodia, leads to a massive induction of
dorsal filopodia. Because the dorsal filopodia induced by Myo10
are not attached to the substrate, Myo10 can promote filopodia by
a mechanism that is independent of substrate attachment. Con-
sistent with this observation, a Myo10 construct that lacks the
FERM domain, the region that binds to integrin, retains the ability
to induce dorsal filopodia. Deletion of the MyTH4-FERM region,
however, completely abolishes Myo10’s filopodia-promoting ac-
tivity, as does deletion of the motor domain. Additional experi-
ments on the mechanism of Myo10 action indicate that it acts
downstream of Cdc42 and can promote filopodia in the absence of
VASP proteins. Together, these data demonstrate that Myo10 is a
molecular motor that functions in filopodia formation.
actin  cytoskeleton  Myo10  microvilli  cell spreading
The finger-like cellular extensions known as filopodia playimportant roles in numerous biological processes including
growth cone guidance (1), wound-healing (2), angiogenesis (3),
and cell–cell signaling (4). Despite these important roles, the
molecular mechanisms underlying the formation of filopodia
and related structures, such as intestinal microvilli and inner ear
stereocilia, are not yet understood (5, 6). Filopodia are known to
contain a core of parallel-bundled actin filaments whose barbed
ends are located at the filopodial tip, and filopodial growth
requires actin polymerization at these barbed ends. The GTPase
Cdc42 is a master regulator of filopodia formation (7) and can
interact with proteins such as N-WASP (Wiskott-Aldrich Syn-
drome Protein) to activate Arp23 and nucleate new actin
filaments (5). Although the branched actin array generated by
activated Arp23 may be important for initiating filopodia (8),
Arp23 is not present on mature filopodial actin bundles (9).
Thus, other proteins such as VASP and formins are likely to
regulate actin polymerization at the tips of filopodia. VASP
family proteins, for example, are present at the tips of filopodia
and can stimulate filopodia formation, presumably because of
their anticapping activity (10, 11). Filopodia formation also
involves actin bundling, and fascin appears to serve as a major
actin bundling protein in filopodia (8).
Myo10 is a vertebrate-specific MyTH4-FERM myosin that is
expressed in most tissues, exhibits a striking localization at the
tips of filopodia, and can undergo movements known as in-
trafilopodial motility within filopodia (12). The Myo10 heavy
chain contains a myosin head domain responsible for motor
activity (13, 14), a neck domain consisting of 3 IQ motifs that
bind to calmodulin light chains, and a unique tail (15). The tail
includes a region predicted to form a coiled coil that can form
dimers (16), 3 PH domains implicated in phosphatidylinositol
3-kinase signaling, a MyTH4 domain that can bind microtubules
(17), and a FERM domain that can bind -integrins (18).
Overexpressing full-length Myo10 increased substrate-attached
filopodia by 4-fold (19), which suggests that Myo10 plays an
important role in filopodia formation. Myo10 could promote
filopodia indirectly by transporting or anchoring integrins at the
filopodial tip (18), therefore stabilizing filopodia by enhancing
substrate attachment. Myo10 also could induce filopodia more
directly, e.g., by functioning as part of a filopodial tip complex
or by transporting molecules required for filopodia formation.
We show here that Myo10 is a potent inducer of dorsal filopodia
and, thus, can induce filopodia independently of effects on
substrate attachment. Furthermore, we show that endogenous
Myo10 is required for formation of normal levels of dorsal
filopodia and acts downstream of Cdc42, thus demonstrating that
this MyTH4-FERM myosin functions in filopodia formation.
Results
Expressing Myo10 Induces a Massive Increase in Dorsal Filopodia. To
test whether Myo10 can directly induce filopodia, we used SEM
as a high-resolution assay to image the filopodia on the dorsal
surfaces of cultured cells (Fig. 1 A–D). Control COS-7 cells
transfected with GFP had virtually no filopodia (1  0.4 dorsal
filopodia per cell), whereas COS-7 cells transfected with GFP-
Myo10 exhibited a massive increase in dorsal filopodia (553 
88). COS-7 cells that expressed higher levels of GFP-Myo10
elaborated more dorsal filopodia (Fig. 1). These data also show
that the substrate-attached filopodia visible along the edges of
cells that we (19) and most other researchers have focused on
previously by using light microscopy sometimes constitute only
a tiny subset of the total filopodia (Fig. 1 C and D). Because
dorsal filopodia are not attached to the substrate, analyzing them
also simplifies interpretation and avoids the difficulties that arise
if substrate-attached filopodia are confounded with retraction
fibers.
To verify that the Myo10-induced extensions are indeed
filopodia, COS-7 cells expressing GFP-Myo10 were stained for
filopodial marker proteins. As expected for filopodia, the ex-
tensions induced by GFP-Myo10 contain F-actin and fascin
along their length and have VASP at their tips (Fig. 1 E–G). To
further verify our assay, COS-7 cells were transfected with
proteins previously reported to induce filopodia and imaged by
SEM. GFP-VASP, GFP-fascin, and constitutively active Cdc42
each induced the formation of numerous dorsal filopodia mor-
phologically similar to those induced by GFP-Myo10 (Fig. 2
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A–C). Similar experiments showed that GFP-Myo10 also induces
dorsal filopodia in many other cell types (data not shown)
including HEK-293 (human embryonic kidney), HUVEC (hu-
man umbilical vein endothelial cells), and CAD cells (a mouse
neuronal cell line). Myo10 therefore promotes formation of
dorsal filopodia in many different cell types and appears to be as
effective as known filopodia inducers such as Cdc42 and fascin.
To determine which domains of Myo10 are required to induce
filopodia, we tested a series of Myo10 deletion constructs for
their ability to induce filopodia in COS-7 cells. Importantly, a
construct lacking the FERM domain, the region that binds to
integrins, was able to induce dorsal filopodia (Fig. 2D). Con-
structs lacking both the MyTH4 and FERM domains, however,
were unable to induce dorsal filopodia (Fig. 2E). Consistent with
this observation, a heavy meromyosin-like Myo10 construct that
consists of only the head, neck, and coiled coil region (PH-
MyTH4-FERM), also failed to induce dorsal filopodia (Fig. 2F).
Because all three deletion constructs localize to the tips of
substrate-attached filopodia (Fig. 6), the failure of the MyTH4-
FERM and the PH-MyTH4-FERM constructs to induce filop-
odia is not due to an inability to localize to filopodia, but instead
is due to deletion of regions in the Myo10 tail required for
filopodia formation.
Knockdown of Myo10 Leads to Loss of Dorsal Filopodia. We next
asked whether endogenous Myo10 is necessary for filopodia
formation. We thus used siRNA to knockdown Myo10 in HeLa
cells, a cell type that elaborates numerous dorsal filopodia under
our standard culture conditions. Densitometry of immunoblots
demonstrated that the Myo10 siRNA specifically knocked down
90% of Myo10 protein by 60–72 h (Fig. 3A). SEM revealed that
HeLa cells treated with control siRNA have numerous dorsal
filopodia per cell (861  37), whereas cells treated with the
Myo10 siRNA exhibit decreased dorsal filopodia (207  23)
(Figs. 3 B and C and 7). These data demonstrate that Myo10 is
required for formation of normal numbers of dorsal filopodia. It
is important to note, however, that the loss of dorsal filopodia
was not complete and that live cell imaging showed that knock-
down cells still were able to extend occasional filopodia (Movies
1 and 2, which are published as supporting information on the
PNAS web site). These results may reflect incomplete knock-
down of Myo10, but it could also indicate that there are
Myo10-independent pathways for filopodia formation.
Expressing a Dominant-Negative GFP-Myo10 Coiled-Coil Construct
Also Leads to Loss of Dorsal Filopodia. As an independent strategy
to confirm that Myo10 functions in filopodia formation, we also
Fig. 1. Expressing Myo10 leads to a massive increase in dorsal filopodia. (A and B) The dorsal surfaces of control COS-7 cells transfected with GFP alone are
smooth and lack dorsal filopodia. (C and D) Cells transfected with GFP-Myo10, however, exhibit a massive increase in dorsal filopodia. A few substrate-attached
filopodia also are visible. (E–G) Fluorescence microscopy demonstrates that the dorsal structures induced by GFP-Myo10 contain known markers of filopodia,
including F-actin (E) and fascin (F), which label filopodial shafts, and VASP (G), which is present in filopodial tips. Note that GFP-Myo10 is visible at the tips of
the numerous dorsal filopodia induced in these cells and, in some cases, forms streaks extending into the filopodial shaft. Although the SEM images in this figure
were obtained from an experiment where FACS was used to isolate transfected cells before SEM, similar results were obtained when fluorescence-correlative
SEM was used to image transfected cells (Figs. 6 A–C and 7A, which are published as supporting information on the PNAS web site).
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developed a dominant-negative approach to inhibit Myo10.
Because we had found that a head-neck construct fails to localize
to filopodial tips whereas a longer construct that includes the
coiled coil does localize to filopodial tips (19), we reasoned that
Myo10 is likely to function as a dimer and that overexpression of
the coiled-coil region therefore might act as a dominant-
negative. We thus generated a GFP-tagged construct from the
putative coiled-coil region of human Myo10. Like Myo10 knock-
down cells, HeLa cells transfected with the GFP-Myo10 coiled-
coil exhibit decreased dorsal filopodia (Fig. 3D). Quantitative
experiments revealed that HeLa cells transfected with GFP had
851  51 dorsal filopodia per cell, whereas cells transfected with
GFP-Myo10 coiled coil had only 331  62 (Fig. 7). It should be
noted that the GFP-Myo10 coiled coil did not localize to
filopodial tips and that expressing a ‘‘control’’ coiled coil from
chicken Myo5a did not reduce dorsal filopodia (data not shown).
The dominant-negative experiments thus provide independent
confirmation that Myo10 is required for formation of normal
numbers of dorsal filopodia.
Inhibiting Myo10 Increases Cell Spreading. In addition to decreased
dorsal filopodia, the most obvious phenotype of HeLa cells
treated with siRNA to Myo10 and replated overnight was an
4-fold increase in cell spreading (Fig. 8, which is published as
supporting information on the PNAS web site). A similar
increase in spread area was observed in HeLa cells transfected
with GFP coiled coil and replated overnight. Because these
results raised the possibility that decreases in dorsal filopodia are
associated with increases in cell spreading, we tested whether
increases in dorsal filopodia are associated with decreases in cell
spreading. We thus transfected COS-7 cells with GFP-Myo10 to
induce dorsal filopodia and replated them for 12 h. These cells
exhibited a 3-fold decrease in their spread area. Although the
precise basis of this effect is not yet clear, it is not due to changes
in cell volume, and expressing GFP-VASP or GFP-fascin led to
similar decreases (Figs. 7 and 8). It thus is likely that the
decreased cell spreading is a consequence of the massive in-
crease in dorsal filopodia induced by all three constructs rather
than a specific effect of Myo10 expression.
Myo10 Acts Downstream of Cdc42. To dissect the molecular mech-
anisms by which Myo10 induces filopodia, we next investigated
the relationship between Myo10 and Cdc42, a master regulator
of filopodia formation. We first verified that constitutively active
Cdc42 induces dorsal filopodia and that dominant-negative
Cdc42 suppresses dorsal filopodia (Fig. 2C and data not shown).
To determine whether Myo10 function requires Cdc42, COS-7
cells were cotransfected with cyan fluorescent protein-Myo10 to
induce dorsal filopodia and dominant-negative GFP-Cdc42 to
inhibit Cdc42. These cells elaborated numerous dorsal filopodia,
indicating that Myo10 acts either independently or downstream
of Cdc42 (Fig. 9, which is published as supporting information on
the PNAS web site). To test whether Myo10 acts downstream of
Cdc42, HeLa cells were treated with siRNA to deplete Myo10
and then transfected with constitutively active Cdc42. Constitu-
tively active Cdc42 was unable to induce filopodia in the absence
of Myo10 (Fig. 4 A and B), suggesting that Myo10 functions
downstream of Cdc42. Importantly, the loss of dorsal filopodia
in HeLa cells treated with siRNA to Myo10 could be rescued by
transfection with the bovine GFP-Myo10 construct (Fig. 4 C and
D), which also provides additional evidence for the specificity of
the Myo10 siRNA. Although GFP-fascin also was able to induce
numerous filopodia in Myo10 siRNA cells, results with GFP-
VASP were less clear (Fig. 10, which is published as supporting
information on the PNAS web site).
Myo10 Can Induce Dorsal Filopodia Independently of VASP Proteins.
Finally, because VASP is present at the tips of filopodia and can
induce dorsal filopodia, we also tested whether Myo10 could
induce filopodia in MVD7 cells, a cell line engineered to lack all
three members of the VASP family (10). Like COS-7 cells,
control MVD7 cells transfected with GFP alone virtually had no
dorsal filopodia (Fig. 5A). MVD7 cells expressing GFP-Myo10,
however, elaborated numerous dorsal filopodia (Fig. 5B). This
result clearly demonstrates that Myo10 can induce dorsal filop-
odia in the absence of VASP proteins.
Discussion
The SEM data presented here demonstrate that Myo10 is a
remarkably potent promoter of dorsal filopodia. These data also
Fig. 2. Expressing VASP, fascin, Cdc42, or a Myo10 construct lacking the FERM domain also lead to massive increases in dorsal filopodia. (A–C) Transfecting
known inducers of filopodia such as GFP-VASP (A), GFP-fascin (B), and constitutively active GFP-Cdc42(61L) (C) in COS-7 cells all lead to massive increases in dorsal
filopodia. Note that in addition to filopodia, the VASP and Cdc42 constructs sometimes also induced small ruffle-like structures. (D–F) Domain-mapping
experiments show that GFP-Myo10 lacking the FERM domain retains the ability to induce dorsal filopodia when expressed in COS-7 cells, whereas GFP-Myo10
lacking the MyTH4 (E) and FERM (D) domains fails to induce filopodia. The GFP-Myo10-heavy meromyosin construct, which lacks the PH, MyTH4, and FERM (F)
domains, also fails to induce filopodia. (G) A hypothetical model of Myo10 as a dimer illustrating its major domains. The SEM images illustrated here and in all
subsequent figures were obtained by using fluorescence-correlative SEM.








demonstrate that Myo10 can promote filopodia via a mechanism
that does not involve stabilization of substrate-attached filopo-
dia. Consistent with this mechanism, deletion of Myo10’s FERM
domain (the region that binds to integrins) did not impair
Myo10’s ability to induce filopodia. Thus, although the FERM
domain and integrin binding may facilitate the formation of
substrate-attached filopodia (18), Myo10 also can induce dorsal
filopodia independently of substrate attachment. Deletion of
both the MyTH4 domain and the FERM domain of Myo10,
however, led to a complete loss of Myo10’s ability to induce
dorsal filopodia, even though this construct was able to localize
to the tips of substrate-attached filopodia. This result suggests
that the MyTH4 domain, one of the defining features of the
MyTH4-FERM myosins, plays an important role in filopodia
formation. Because deletion constructs that lack the Myo10
motor domain fail to localize to filopodial tips and do not induce
filopodia (19), our results support a model for Myo10 function
where the motor domain is required to properly localize the tail
domain, and a properly localized tail is required for filopodia
formation.
We also show here that endogenous Myo10 is necessary for
formation of normal numbers of dorsal filopodia by using two
independent strategies, Myo10 siRNA and a dominant-negative
construct. These results, together with the data showing that
Myo10 is a potent inducer of filopodia, demonstrates that Myo10
functions as a molecular motor for filopodia formation. Our
work also raises the question of how Myo10 acts to promote
filopodia. Our data indicate that Myo10 acts downstream of
Cdc42, a regulator of filopodia that acts upstream of actin
nucleators such ARP23 (20) and formins (21) and also stimu-
lates actin bundling (6). Because Myo10 is an actin-based motor
and its motor is necessary for filopodia induction, Myo10 may act
on actin generated downstream of Cdc42 action. In the conver-
gent elongation model of filopodia formation, branched actin
filaments nucleated by Arp23 associate via their tips to form
‘‘-precursors’’ proposed to initiate filopodia (8). Although
VASP is present at the tips of -precursors (8), the protein(s)
that lead the tips of actin filaments to associate with one another
in -precursors remain unknown. Like VASP, Myo10 is present
at the tips of nascent filopodia as soon as they can be detected
(19). As expected for a component of -precursors, puncta of
GFP-Myo10 recently have been observed to move laterally along
the leading edge, where they collide and fuse (22). Because our
data show that Myo10 can induce dorsal filopodia in the absence
of VASP proteins, Myo10 may be a component of -precursors
and, thus, function in filopodial initiation. If Myo10 promotes
filopodia by ‘‘focusing’’ the barbed ends of actin filaments into
-precursors, our results show that Myo10’s heads are not
sufficient for this activity because the heavy meromyosin-like
construct consisting only of the head, neck, and coiled coil is
unable to induce dorsal filopodia (Fig. 2F). It also should be
noted that although convergent elongation provides a useful
conceptual model for filopodia formation, the nature of the actin
network underlying dorsal filopodia is not yet clear and it may
differ from the dendritic array observed at the leading edge. It
thus will be important to consider other mechanisms by which
Myo10 could promote filopodia, such as by deliveringlocalizing
materials required for polymerization to the filopodial tip,
interacting with formins, or by pushing the plasma membrane
away from the ends of growing actin filaments to facilitate
monomer insertion.
Conserved Functions of MyTH4-FERM Myosins in Filopodia and Related
Structures. Like Myo10, other MyTH4-FERM myosins may
have similar functions in the formation of filopodia and related
Fig. 3. Inhibiting Myo10 suppresses dorsal filopodia. (A) Immunoblot of
HeLa cells treated with control or Myo10 siRNA showing specific knockdown
of Myo10. Samples were run with a 4–20% SDSPAGE, transferred to nitro-
cellulose, and stained with Ponceau to reveal total protein and then blotted
with anti-Myo10 to confirm knockdown. (B) SEM of a HeLa cell from the same
experiment treated with control siRNA showing the numerous dorsal filopo-
dia normally present on these cells. (C) SEM of a HeLa cell from the same
experiment treated with Myo10 siRNA showing the loss of dorsal filopodia
induced by Myo10 siRNA. (D) SEM of a HeLa cell illustrating the loss of dorsal
filopodia observed in HeLa cells expressing the dominant-negative GFP-
Myo10 coiled-coil construct.
Fig. 4. Myo10 acts downstream of Cdc42. (A) Like untreated HeLa cells, HeLa
cells treated with a control siRNA and then transfected with constitutively
active GFP-Cdc42 exhibit numerous dorsal filopodia. (B) Parallel samples
treated with the Myo10 siRNA, however, have very few dorsal filopodia, even
in the presence of constitutively active GFP-Cdc42, indicating that Myo10
functions downstream of Cdc42. (C and D) The loss of dorsal filopodia induced
by the siRNA to human Myo10 (C) can be rescued by transfection with bovine
GFP-Myo10 (D). Note that the constitutively active GFP-Cdc42(61L) construct
used here led to a massive induction of filopodia in other situations (Fig. 2C).
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structures such as microvilli and stereocilia. Experiments with
human Myo15, a MyTH4-FERM myosin that is expressed in
the inner ear, show that it localizes to the tips of stereocilia (23,
24), is necessary for proper stereociliary elongation, and
exhibits movements within filopodia strikingly similar to the
intrafilopodial motility of Myo10 (25). Loss of a Drosophila
MyTH4-FERM myosin, myosin-VIIa, is the basis of crinkled,
a usually lethal mutation where escapers exhibit defects in
bristles and other structures derived from actin bundles (26).
Another MyTH4-FERM myosin, myosin-VIIb, localizes to the
microvilli of secretory epithelial cells (27). Finally, deletion of
Dictyostelium myosin-VII leads to a 90% loss of filopodia and
dramatic defects in adhesion and phagocytosis (28, 29). To-
gether with the work on Myo10 presented here, these data
provide strong evidence that MyTH4-FERM myosins have
ancient and highly conserved functions in membrane–
cytoskeleton interactions underlying the formation of filopo-
dia and related structures.
Materials and Methods
Constructs. Human GFP-fascin in pEGFP-C1 (30), human GFP-
VASP in pEGFP-N1 (8), untagged bovine Myo10 in pcDNA3.1,
and the bovine GFP-Myo10, GFP-Myo10-heavy meromyosin,
GFP-Myo10 tail, and GFP-Myo10 headless constructs in
pEGFP-C2 have been described in ref. 19. The bovine GFP-
Myo10 construct was converted to cyan fluorescent protein-
Myo10 by replacing GFP with cyan fluorescent protein. The
bovine GFP-Myo10 FERM construct in pEGFP-C2 includes
amino acids 1–1916, and the GFP-Myo10 MyTH4-FERM
construct in pEGFP-C2 includes amino acids 1–1523. The
GFP-Myo10 coiled-coil construct in pEGFP-C2 includes amino
acids 812–946 and was generated by PCR from human Myo10
(31), and the control GFP-Myo5a coiled-coil construct includes
amino acids 913-1116 of chicken Myo5a. The dominant-negative
human GFP-Cdc42(15A) (32) and the constitutively active GFP-
Cdc42(61L) in pEGFP-C3 were generous gifts of Keith Burridge
(University of North Carolina, Chapel Hill). Because the GFP-
Cdc42(15A) construct appeared to be more effective than a
Myc-Cdc42(N17) construct in suppressing dorsal filopodia in
HeLa cells, the 15A construct was used here.
Transfection. All cells were transfected with cDNA constructs by
using Polyfect (Qiagen, Valencia, CA) except for MVD7 cells,
which were transfected by using the Amaxa nucleoporation
protocol for mouse embryonic fibroblasts. After the overnight
transfections, cells were trypsinized and replated onto glass
coverslips for 12 h in the presence of serum before fixation. For
fluorescence-correlative SEM, the cells were plated onto 12-mm
gridded round glass coverslips, (Eppendorf-USA, Westbury,
NY), whereas cells sorted by FACS were plated onto 12-mm
round glass coverslips. Although COS-7 cells normally lack
dorsal filopodia, during mitosis, they round up and elaborate
numerous dorsal filopodia, so mitotic cells were excluded from
our analysis (3% of cells). Quantitative immunoblotting with
anti-Myo10 indicated that COS-7 cells express 65% as much
endogenous Myo10 as HeLa cells and that the average level of
overexpression with GFP-Myo10 in COS-7 cells was 100-fold.
Similar blots indicated that the GFP-Myo10 coiled coil was
overexpressed at least 30 fold, and blots with anti-GFP indi-
cated that the GFP-Myo5a coiled coil was expressed at approx-
imately the same level.
Knockdown of Myo10 by Using siRNA. A synthetic siRNA targeting
human Myo10 (5-AAGTGCGAACGGCAAAAGAGA-3)
that differs at 7 positions from bovine Myo10 and a control
siRNA (5-AATTCTCCGAACGTGTCACGT-3) were ob-
tained from Qiagen with fluorescein tags at their 3 ends. A day
before siRNA treatment, 100,000 cells per well were plated
onto six-well plates at 50–60% confluency and incubated at 37°C
for 12 h. Cells were then treated with a final concentration of
110–150 nM siRNA by using RNAifect (Qiagen) following the
manufacturer’s instructions. The media was replaced 16 h after
transfection, and fluorescence microscopy was used to verify that
100% of the cells had taken up the siRNA. At 48 h, the cells
from each well were replated, typically into 18 wells of a 24-well
plate containing 12-mm glass coverslips. At 60–72 h, cells were
processed for scanning EM or light microscopy, and parallel
samples were assayed by immunoblotting to verify knockdown.
For siRNA experiments that also involved transfection with an
expression plasmid, siRNA-treated cells were transfected with
GFP-Myo10 or constitutively active GFP-Cdc42 constructs at
48 h. Cells were allowed to grow overnight after transfection,
replated onto glass coverslips for 12 h, and then fixed and
processed for fluorescence-correlative SEM.
SEM Experiments. SEM experiments to test the filopodia promot-
ing activity of GFP-Myo10 and other constructs were performed
by using three different approaches (1). For preliminary com-
parative experiments, cells were transfected overnight with
Polyfect and then replated for 12 h onto 12-mm coverslips. The
transfection efficiency for each construct was assessed by fluo-
rescence microscopy of one coverslip and compared with the
fraction of cells exhibiting dorsal filopodia on a duplicate
coverslip prepared for SEM. Because control COS-7 cells nor-
mally lack dorsal filopodia, this approach provided a simple and
rapid screen for filopodia induction, especially when the trans-
fection efficiency exceeded 30%. This method also allowed us
to determine that the untagged bovine construct is a potent
inducer of dorsal filopodia (2). For the FACS approach, cells in
six-well dishes were transfected overnight by using Polyfect,
trypsinized, and subjected to FACS. The transfected cells were
replated onto 12-mm coverslips for 12 h and then prepared for
SEM. This approach provided the advantage for scanning EM
that 100% of the cells on a given coverslip were transfected (3).
For the fluorescence-correlative SEM approach, cells were
transfected overnight and then replated for 12 h on gridded
coverslips. Coverslips were rinsed briefly with PBS, prefixed
3.7% paraformaldehyde for 5 min at room temperature, and
then rinsed three times with PBS. To identify and record the
Fig. 5. Myo10 can induce dorsal filopodia in the absence of VASP family
proteins. (A) EnaVASP null cells (MVD7) transfected with GFP alone exhibit
very few dorsal filopodia. (B) EnaVASP null cells transfected with GFP-Myo10,
however, exhibit numerous dorsal filopodia, thus demonstrating that Myo10
does not require VASP proteins for its filopodia promoting activity.








positions of individual transfected cells, the coverslips then were
placed cell side up in a glass bottom dish (Willco, Amsterdam,
The Netherlands) and imaged with fluorescence by using an
inverted microscope and a 20  0.75 NA dry lens (Nikon,
Melville, NY). Coverslips then were prepared for SEM by using
standard procedures, and SEM images of the transfected cells
were collected. Because this correlative approach worked well
even when transfection efficiencies were low and it provided the
additional internal control of untransfected cells on each cov-
erslip, it was used for most experiments.
Supporting Information. Supporting Materials and Methods, which
is published as supporting information on the PNAS web site,
provides additional details on the constructs, cell culture con-
ditions, and microscopy procedures used here.
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